Prostate Cancer

Staying educated in the formal and informal health care settings surrounding state-of-the-art cancer care in the community practice is essential for success.

The study also analyzed the relationship between ultra-processed food and drink products with 2 other cancer types.

Clinicians have been searching for accurate, reliable, non-invasive diagnostic tools to differentiate early stage, less dangerous, and more treatable stages of the disease from the aggressive, high-grade and likely-to-spread forms.

Angelo Moore, PhD, MSN, RN, NE-BC, program manager, Office of Health Equity at Duke Cancer Institute, discussed how one of his goals was to truly involve the community in educating others on the clinical guidance, primarily for prostate cancer screenings.

Addressing genomic differences and socioeconomic disparities is essential in order to address the higher incidences and mortality rates for prostate cancer among African American men.

Researchers from the University of Texas MD Anderson Cancer Center found that men with localized prostate cancer who reported a baseline dietary pattern that more closely follows the key principles of a Mediterranean-style diet fared better over the course of their disease.

Relugolix is the first oral drug in this class to receive FDA approval, and it may eliminate some patients’ need to visit the clinic for certain treatments.

FDA approves Gallium 68 PSMA-11, the first drug for PET imaging of prostate-specific membrane antigen–positive lesions in patients with prostate cancer.

FDA lift clinical hold placed on the phase 1 PSMA-101-001 study of the chimeric antigen receptor T-cell therapy P-PSMA-101 in patients with metastatic castration-resistant prostate cancer.

Bacteria in the gut may play a role in the treatment outcomes of patients with prostate cancer taking oral medications, according to a recent study.

The FDA grants fast track designation to the highly-selective N-terminal domain inhibitor EPI-7386 for the treatment of adult patients with metastatic castration-resistant prostate cancer.

Since 2004, the FDA has approved different treatments for advanced prostate cancer, adding almost 2-3 indications per year for the past 15 years.

On February 14, 2018, the FDA approved apalutamide (Erleada) by Janssen Biotech Inc for the treatment of nonmetastatic castration-resistant prostate cancer (NM-CRPC).